Tikcro Technologies

Company Overview

Snapshot

Founded in December 1999, Tikcro Technologies operates with 1–10 employees. The company was delisted from the OTC stock exchange in May 2021, ceasing operations.

Business overview

Tikcro Technologies specializes in Health Tech & Life Sciences, focusing on the development of new functional blocking antibodies. The company leverages a novel 3D antigen design technology to generate antibodies that block receptor/ligand surface domains of immune modulators. This technology aims to reactivate the body's immune system to combat cancer, serving the pharmaceuticals and biotechnology sectors within the healthcare and life sciences markets.

Strategic signal

In February 2023, Tikcro Technologies announced a liquidating dividend, signaling the final stages of its operational cessation. This event confirms the company's non-active status and provides a clear indication to investors regarding the wind-down of its business activities.

Company Intelligence Q&A

What is Tikcro Technologies' primary focus?

Tikcro Technologies focuses on developing new functional blocking antibodies using a novel 3D antigen design technology to re-activate the body's immune system against cancer.

When did Tikcro Technologies cease operations?

Tikcro Technologies ceased to operate in May 2021, at which point it was delisted from the OTC stock exchange.

What was a significant recent corporate action by Tikcro Technologies?

In February 2023, Tikcro Technologies announced a liquidating dividend, indicating the final distribution of assets as the company winds down its operations.

Where did Tikcro Technologies establish new offices and a lab in 2016?

In February 2016, Tikcro Technologies opened new offices and a lab at the Kiryat Weizmann Science Park in Israel.

What was a notable event in Tikcro Technologies' early history regarding its public status?

In April 2003, Tikcro Technologies underwent a reverse merger event with Orckit Corrigent, leading to its listing on the OTC stock exchange.